Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Neratinib,Capecitabine,Loperamide Hydrochloride
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
New Breast Cancer Therapy Approved in Thailand to Reduce Recurrence Risk
Details : Nerlynx (neratinib) is a kinase inhibitor indicated for the extended adjuvant treatment of adult patients with early stage HER2 overexpressed/amplified breast cancer.
Product Name : Nerlynx
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 11, 2025
Lead Product(s) : Neratinib,Capecitabine,Loperamide Hydrochloride
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Lonapegsomatropin
Therapeutic Area : Endocrinology
Study Phase : Approved FDF
Sponsor : Ascendis Pharma
Deal Size : Undisclosed
Deal Type : Agreement
Specialised Therapeutics Signs Agreement for Three Endocrinology Therapies
Details : Specialised Therapeutics will commercialize Ascendis' injectable pediatric growth hormone SKYTROFA, hypoparathyroidism treatment YORVIPATH, and investigational therapy TransCon CNP.
Product Name : Skytrofa
Product Type : Hormone
Upfront Cash : Undisclosed
July 01, 2024
Lead Product(s) : Lonapegsomatropin
Therapeutic Area : Endocrinology
Highest Development Status : Approved FDF
Sponsor : Ascendis Pharma
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Oregovomab,Carboplatin,Paclitaxel
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : CanariaBio
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Under the terms of the arrangement, ST will be responsible for all commercial, medical, regulatory and distribution activities for oregovomab in its key territories of Australia, New Zealand, Singapore, Thailand, Vietnam, Brunei and Malaysia.
Product Name : MAb-B43.13
Product Type : Antibody
Upfront Cash : Undisclosed
December 10, 2023
Lead Product(s) : Oregovomab,Carboplatin,Paclitaxel
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : CanariaBio
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Tafasitamab,Lenalidomide
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lymphoma Therapy Now Approved for Australian Patients with Diffuse Large B-Cell Lymphoma
Details : Monjuvi® and Minjuvi® (tafasitamab) is a humanized Fc-modified CD19 targeting immunotherapy used in combination with lenalidomide for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma.
Product Name : Minjuvi
Product Type : Antibody
Upfront Cash : Inapplicable
June 28, 2023
Lead Product(s) : Tafasitamab,Lenalidomide
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Trabectedin
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Global Sarcoma Therapy Now Approved for New Zealand Patients
Details : Yondelis (trabectedin) binds guanine residues in the minor groove of DNA, forming adducts and resulting in a bending of the DNA helix triggering a cascade of events like DNA repair pathways, resulting in perturbation of the cell cycle and eventual cell d...
Product Name : Yondelis
Product Type : Cytotoxic Drug
Upfront Cash : Inapplicable
February 17, 2023
Lead Product(s) : Trabectedin
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ripretinib
Therapeutic Area : Gastroenterology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
New Therapy to Treat Rare Gastrointestinal Stromal Tumour Approved for New Zealand Patients
Details : Qinlock (ripretinib) is a switch-control tyrosine kinase inhibitor that was engineered to broadly inhibit KIT and PDGFRA mutated kinases, involved in GIST, by using a dual mechanism of action that regulates the kinase switch pocket and activation loop.
Product Name : Qinlock
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 20, 2023
Lead Product(s) : Ripretinib
Therapeutic Area : Gastroenterology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tafasitamab,Lenalidomide
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Incyte Corporation
Deal Size : Undisclosed
Deal Type : Agreement
Details : Under the terms of the agreement, Incyte will be responsible for the development, manufacture and supply of both products tafasitamab (sold as Monjuvi) and pemigatinib (Pemazyre) and ST will be responsible for regulatory, distribution and local marketing...
Product Name : Minjuvi
Product Type : Antibody
Upfront Cash : Undisclosed
October 22, 2021
Lead Product(s) : Tafasitamab,Lenalidomide
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Incyte Corporation
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Lurbinectedin
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : PharmaMar
Deal Size : Inapplicable
Deal Type : Inapplicable
New Therapy to Treat Advanced Small Cell Lung Cancer ZEPZELCA® (lurbinectedin) Approved in Singapore
Details : ZEPZELCA® (lurbinectedin) is an alkylating drug that binds guanine residues within DNA. This triggers cascade of events that can affect activity of DNA binding proteins, including some transcription factors to treat 2L metastatic small cell lung cancer.
Product Name : Zepzelca
Product Type : Cytotoxic Drug
Upfront Cash : Inapplicable
September 22, 2021
Lead Product(s) : Lurbinectedin
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : PharmaMar
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Lurbinectedin
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : PharmaMar
Deal Size : Inapplicable
Deal Type : Inapplicable
New Therapy to Treat Advanced Small Cell Lung Cancer Approved for Australian Patients
Details : ZEPZELCA® (lurbinectedin) is the first new therapy approved to treat second-line metastatic SCLC in Australia in more than 20 years. ZEPZELCA approval granted under a provisional regulatory pathway.
Product Name : Zepzelca
Product Type : Cytotoxic Drug
Upfront Cash : Inapplicable
September 14, 2021
Lead Product(s) : Lurbinectedin
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : PharmaMar
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Trabectedin
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
GLOBAL Sarcoma Therapy Now Approved for Australian Patients
Details : The Therapeutic Goods Administration has approved the use of YONDELIS (trabectedin), marketed by Specialised Therapeutics, "for the treatment of patients with unresectable or metastatic liposarcoma or leiomyosarcoma who received a prior anthracycline-con...
Product Name : Yondelis
Product Type : Cytotoxic Drug
Upfront Cash : Inapplicable
April 23, 2021
Lead Product(s) : Trabectedin
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable